Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 3/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | AHCY | P23526 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510823 | 1.00 | TNK2 (0.35) | TNK2HSPA5RETAHCYAXL | |
| SCHEMBL19758149 | 0.87 | TSHR (0.31) | TNK2 | |
| SCHEMBL17131351 | 0.87 | TSHR (0.31) | TNK2 | |
| SCHEMBL10120838 | 0.86 | TNK2 (0.35) | TNK2HSPA5NTRK1NTRK2 | |
| SCHEMBL18371662 | 0.86 | TNK2 (0.35) | TNK2HSPA5NTRK1NTRK2 | |
| SCHEMBL17719386 | 0.86 | TNK2 (0.35) | TNK2HSPA5NTRK1NTRK2 | |
| SCHEMBL10120675 | 0.86 | TNK2 (0.35) | TNK2HSPA5NTRK1NTRK2 | |
| SCHEMBL20434838 | 0.83 | PDE2A (0.38) | TNK2HSPA5 | |
| SCHEMBL21759078 | 0.83 | PDE2A (0.38) | TNK2HSPA5 | |
| SCHEMBL24539016 | 0.83 | PDE2A (0.38) | TNK2HSPA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | TNK2 1069/4885HSPA5 2853/4885RET 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.